Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation.

Details

Ressource 1Download: Raloxifène-fxvl 2018-CasesRepRheumatol.pdf (1514.48 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_E25ED86031BF
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation.
Journal
Case reports in rheumatology
Author(s)
Gonzalez-Rodriguez E., Stoll D., Lamy O.
ISSN
2090-6889 (Print)
ISSN-L
2090-6897
Publication state
Published
Issued date
2018
Peer-reviewed
Oui
Volume
2018
Pages
5432751
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
At denosumab discontinuation, an antiresorptive agent is prescribed to reduce the high bone turnover, the rapid bone loss, and the risk of spontaneous vertebral fractures. We report the case of a woman treated with aromatase inhibitors and denosumab for 5 years. Raloxifene was then prescribed to prevent the rebound effect. Raloxifene was ineffective to reduce the high bone turnover and to avoid spontaneous clinical vertebral fractures. We believe that among the antiresorptive treatments, the most powerful bisphosphonates should be favored, and their administration adapted according to the serial follow-up of bone markers.
Pubmed
Open Access
Yes
Create date
17/10/2018 9:32
Last modification date
21/08/2019 6:10
Usage data